Healthcare News

AUSTIN, Texas, Oct. 23, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief Executive Officer...

Durable responses observed across multiple tumor types during dose escalationMGC026 demonstrated 27% best overall response rate (6/22 patients; 4 confirmed and 2 unconfirmed PRs) in heavily pretreated...

Initial and updated cohort data from ongoing Phase 1/2 study of highly selective non-brain-penetrant PARP1 inhibitor EIK1003 continue to support potentially differentiated profile of EIK1003 in...

Transactions position the company to advance Prana’s pipeline of next-generation, half-life-extended multispecific antibodies enabled by its proprietary INSPIRE platformPRA-216 is a novel IL-4Rα/TSLP...

Multiple pre-specified subgroup analyses favored camupepimut (ELI-002 7P), including patients with and without detectable baseline ctDNA.Encouraging disease-free survival outcomes were observed in...

Additional $500,000 Advance to Support Growth Initiatives and Working Capital of Realbotix LLC Total Drawn Under Facility Now $3,000,000; Non-Interest Bearing Facility Automatically Cancelled and...

ORLANDO, Fla., Oct. 23, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 third quarter financial results before the market opens on...

 -- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study...

Completion of light dose-escalation Part A of Phase 1 study identifies regimen for further evaluation in Part B, supporting advancement of Padeliporfin VTP for treatment of locally advanced pancreatic...

- The presenter, Dr. Roy-Chaudhury said, “These results give the nephrology community a strong reason to rethink our approach to access decisions for women and, once approved by the FDA, to consider...